Equilibra Bioscience is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-activated Protein C (APC) monoclonal antibody (mAb) therapeutic for inherited and/or acquired bleeding disorders including Hemophilia A/B.